Could Forest's DDMAC Letter For Off-Label Promotion Doom CEO Solomon?
This article was originally published in The Pink Sheet Daily
A physician complained to FDA's "Bad Ad" program about a Forest Laboratories sales representative's off-label claims for the fibromyalgia drug Savella.
You may also be interested in...
The agency says the violation occurred despite FDA’s criticism of proposed promotional material for the respiratory drug and an ongoing corporate integrity agreement intended to block improper promotion.
While admitting that Sunovion Pharmaceuticals Inc.’s schizophrenia drug Latuda (lurasidone) does not yet have an indication for bipolar I disorder, a sales rep told a psychiatrist it could still be used to treat that condition, FDA’s Office of Prescription Drug Promotion says in a “notice of violation” letter.
In its first year of operation, FDA's "Bad Ad" program succeeded in more than tripling the number of complaints the agency receives about deceptive drug advertising, and now the agency is assessing how best to expand upon the success of the initiative.